The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with...

First targeted therapy available for the treatment of two main types of ANCA-associated vasculitis (AAV), a rare and systemic disease

Vifor Pharma AG ("Vifor") announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly held registered shares of Vifor with a nominal value of CHF 0.01 each (each a "Vifor Share").

China has the world’s largest iron deficiency anemia population with estimated prevalence of 15%1 Approval may also benefit the Chinese healthcare system, among others through implementation of...

Iron Deficiency Day unites a strong international coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia1 This year, the focus is on importance of...